In conclusion, simultaneous inhibition of PI3K, mTORC1 and mTORC2 by the dual inhibitors NVP-BEZ235 and NVP-BGT226 exerts profound antileukemic activity against a broad spectrum of B-precursor ALL, irrespective of genetic subtype and – in the case of BCR-ABL positive ALL – their degree of responsiveness or resistance to clinically established ABL-kinase inhibitors. The gene discussed is PIK3CA; the disease is acute lymphoblastic leukemia.